BARCELONA—Healthy women with BRCA1 mutations who opted for bilateral prophylactic mastectomy had their lives prolonged in comparison with similar women who did not. But in healthy women with the BRCA2
BARCELONA—Healthy women with BRCA1 mutations who opted for bilateral prophylactic mastectomy had their lives prolonged in comparison with similar women who did not. But in healthy women with the BRCA2 mutation the procedure did not improve overall survival even though it reduced their risk of breast cancer in the next ten years. These findings were reported at the 2018 European Breast Cancer Conference from an analysis of the Netherlands national Hereditary Breast and Ovarian Cancer Netherlands (HEBON) database.
First author Annette Hemskerk-Gerritsen PhD, a post-doctoral researcher at Erasmus Medical Center in Rotterdam, discusses the clinical implications of the study for the Audio Journal of Oncology.